Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (331-340 of 351) with videos related to

Pageof 36
Sort By:
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
The British Journal of Dermatology|May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasisC Ryan, A Menter, L Guenther, et al.
Arthritis Care & Research|October 20, 2019
Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus StudyCandace H Feldman, Cameron Speyer, Rachel Ashby, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2023
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual MeetingKathryn Lee, Michael J Woodbury, Melissa Peri Zundell, et al.
JAMA Dermatology|June 22, 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic ReviewAdam R Ford, Michael Siegel, Jerry Bagel, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic ArthritisLaura C Coates, Oliver FitzGerald, Joseph F Merola, et al.
The Journal of Rheumatology|June 15, 2024
Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept StudyDan E Webster, Rebecca H Haberman, Lourdes M Perez-Chada, et al.
Pageof 36

Showing results (331-340 of 351) with videos related to

Sort By:
Pageof 36
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
The British Journal of Dermatology|May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasisC Ryan, A Menter, L Guenther, et al.
Arthritis Care & Research|October 20, 2019
Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus StudyCandace H Feldman, Cameron Speyer, Rachel Ashby, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2023
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual MeetingKathryn Lee, Michael J Woodbury, Melissa Peri Zundell, et al.
JAMA Dermatology|June 22, 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic ReviewAdam R Ford, Michael Siegel, Jerry Bagel, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic ArthritisLaura C Coates, Oliver FitzGerald, Joseph F Merola, et al.
The Journal of Rheumatology|June 15, 2024
Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept StudyDan E Webster, Rebecca H Haberman, Lourdes M Perez-Chada, et al.
Pageof 36